Activation of ␣ 1-adrenoceptors facilitates excitatory inputs to medullary airway vagal preganglionic neurons.
IN MAMMALS INCLUDING HUMANS, the neural regulation of the lower airway is dominated by the vagus nerves (6, 31) and a subset of medullary AVPNs located in the eNA that are particularly important in controlling airway smooth muscle (12, 13, 16, 19, 20) . AVPNs are intrinsically silent, and their spontaneous or phase-locked inspiratory activity relies completely on their synaptic inputs, including excitatory glutamatergic and inhibitory ␥-aminobutyric acidergic and glycinergic inputs (9, 10, 17, 25, 36) . During the inspiratory phase, the majority of AVPNs are activated by bursting excitatory inputs and called IA-AVPNs, and the minority of AVPNs are inhibited by bursting inhibitory inputs and are therefore called II-AVPNs (9) .
In many regions of the central nervous system, excitatory neurotransmission is inhibited by activation of presynaptic ␣ 2 -adrenoceptors (2, 3, 30) but facilitated by activation of presynaptic ␣ 1 -adrenoceptors (4, 8, 32, 35) . AVPNs are also physiologically modulated by central adrenergic/noradrenergic projections. In rats, application of transsynaptic pseudorabies virus to the extrathoracic trachea labels both medullary and pontine catecholaminergic neurons (11, 13) . In ferrets, the AVPNs in the eNA express ␣ 2A -adrenoceptors; catecholaminergic terminals or varicosities are found in the close vicinity of these neurons, although they seldom form synapses with them, and stimulation of the LC increases noradrenaline release in the eNA and decreases airway muscle tension (14, 34) . Moreover, in a ferret model of allergic asthma, the expression of ␣ 2A -adrenoceptors is downregulated in the eNA, and local microperfusion of an ␣ 2A -adrenoceptor agonist blunts the decrease in airway muscle tension (34) . Consequently, attenuated ␣ 2 -adrenergic inhibition of the AVPNs, which might become worse during sleep due to reduced or silenced pontine noradrenergic activity, is suggested to be involved in not just the pathogenesis of asthma, but also in its sleep-related worsening (15, 34) .
Meanwhile, although it is unknown whether AVPNs receive ␣ 1 -adrenergic excitatory modulation, the possibility has been suggested by some previous studies. In rats challenged with CIC or CIH, the activation of central noradrenergic neurons by subsequent stress exposure is sensitized (22, 24) , and the density of noradrenergic terminals and ␣ 1 -adrenoceptor immunoreactivity is increased in several other brainstem nuclei that receive noradrenergic projections, such as the trigeminal sensory and motor nuclei and the hypoglossal nuclei (23, 26, 28) . Coincidently, CIC is well recognized as an inducing or triggering factor of asthma in both humans and experimental animals, and CIH is indicated to be the triggering factor of nocturnal asthma and cough in some patients with obstructive sleep apnea syndrome (5, 7, 29) . It is thus reasonable to assume that AVPNs are also modulated by ␣ 1 -adrenergic actions. And, if so, the ␣ 1 -adrenergic actions very likely include facilitation of the excitatory inputs.
In view of the potential importance of the putative ␣ 1 -adrenergic modulation of AVPNs, it becomes necessary to validate this modulation and elucidate the mechanism of action at neuronal and synaptic levels. The present study thus aimed at testing the hypotheses that selective activation of ␣ 1 -adrenoceptors in the eNA of rats increases airway vagal tone in vivo, and that this effect involves facilitation of the excitatory presynaptic inputs to AVPNs. Sciences, 1996) . Sprague-Dawley rats were obtained from the Experimental Animal Center of the Chinese Academy of Science in Shanghai and raised on a 12:12-h light-dark cycle with food and water available ad libitum. A total of 73 newborn rats of either gender and 12 male adult rats were used in this study. The researchers involved in this study made special efforts to minimize the number of animals used and their suffering.
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Microinjection surgery and evaluation of airway resistance in adult rats. The 3-to 4-mo-old male rats weighing 320 to 350 g were anesthetized by injection of 10% chloral hydrate in saline (360 mg/kg ip). The level of anesthesia was assessed by an absence of the withdrawal reflex and by the suppression of changes in breathing rate and heart rate in response to noxious stimuli, and maintained by subcutaneous injection of chloral hydrate hourly at 90 mg/kg. The larynx was denervated, separated from the pharynx, and moved aside. A Y-type tracheal cannula (2.5 mm ID) was inserted into the trachea through the larynx. Under this condition, spontaneous breathing was unaffected by upper airway afferents. The rats were placed in a supine position in a stereotaxic frame (Neurostar Instruments, Tubingen, Germany). Rectal temperature was monitored with a thermometer, and maintained at 37.0 -37.4°C with a thermopad placed under the back. The basal aspect of the occipital bone was removed to expose the ventral aspect of the medulla. A glass micropipette (tip diameter 30 -40 m) filled with drug solution was connected to a microsyringe through polyethylene tubing and fixed onto the vertical axis of the stereotaxic instrument. Under the guidance of the stereotaxic instrument, the tip of the micropipette was conducted into the unilateral AVPN-containing region (2 mm lateral to the midline, 750 m caudal to the most rostral root of the hypoglossal nerve, and 750 m dorsal to the ventral surface) as described in the previous study (18) , and 100 nl of the drug solution was injected with pressure (250 -300 mmHg) in a 15-to 20-s period when appropriate.
One branch of the tracheal cannula was connected through a segment of polyethylene tubing (2.5 mm ID, 3.5 cm length) to the plethysmographic chamber (4,665 ml volume) from the outside to analyze pulmonary function using the Anires2005 system (Beijing Biolab, Beijing, China). The other branch was connected to the pressure-detecting channel of the system. This system automatically calculates and displays pulmonary function parameters such as tidal volume, respiratory rate, and airway resistance on the basis of changes detected. Under this animal-out manner of installation, animals breathe the air in the chamber, pulmonary function parameters are measured in individual animals by the system, and in absolute terms, the values measured by the system are indistinguishable from those measured in a usual, whole-body manner of plethysmography. The O 2 content inside the chamber was enriched to 27 Ϯ 1% with 100% O2 in advance, and monitored continuously with a portable O2 analyzer (50 ml in volume; Beixin Future Electronics Technology Center, Beijing, China) placed inside. A fresh mixture of CaO and NaOH (100 g; in 99:1) was placed in the chamber to instantly absorb the exhaled H 2O and CO2. The pressure inside and outside the chamber was equilibrated through a hole (0.5 mm diameter) in the chamber wall. Under this condition, the O 2 content inside the chamber was above 21% during the entire experiment, which usually takes 30 -45 min. Heart rate, respiratory rate, and tidal volume of the animals remained stable unless they were pharmacologically perturbed.
At the end of the experiment, 100 nl of 1% pontamine sky blue in ACSF was injected into the same site at which the drug was injected. After the experiment, the rat was killed by overdose with an intraperitoneal injection of chloral hydrate, and perfused through the left heart ventricle with 50 ml of 0.2% heparin sodium in PBS. The brainstem was then removed and kept in 2.5% glutaraldehyde in PBS for 24 -48 h. After that, slices (100 m) were cut to verify the injection site.
Retrograde fluorescent labeling of AVPNs in newborn rats. AVPNs were retrogradely labeled as we previously described (9, 10) . Briefly, halothane, a volatile anesthetic agent, was dripped onto a cotton pad placed at the bottom of a glass box (5 ϫ 5 ϫ 5 cm). Sprague-Dawley rats (2 to 3 days old) were placed into the box for 30 s with the lid loosely closed. This procedure anesthetized the rats but allowed them to breath spontaneously. When the rats no longer showed any response to pinching on their limbs, the bodies were wrapped in cold plastic bags filled with ice-water mixture to decrease the body temperature and slow the heart rate. After spontaneous breathing stopped (usually within 2 min), the animal was fixed on a cold plastic bag in a supine posture. A ventral midline incision was made in the neck to expose the extrathoracic trachea, and rhodamine [X-rhodamine-5-(and-6)-isothiocyanate; Molecular Probes, 1% solution, 0.5 l] was injected into the trachea wall between the fourth and eighth tracheal cartilage using a glass pipette (tip diameter 30 m) attached to a syringe through polyethylene tubing. The incision was rinsed with saline containing 5 mg/ml streptomycin sulfate and 50,000 U/ml penicillin, and sutured. Afterward, the animals were warmed with a thermo-pad to help recovery. The entire surgical period took less than 5 min per animal, during which the body temperature of the animals was below 10°C, the animals had no spontaneous breathing, and did not struggle. After the surgery, the animals usually resumed spontaneous breathing within 3 min and moved freely within 5 min. A single dose of morphine (10 mg/kg ip; Qinghai Pharmaceutical, Qinghai, China) was injected to relieve postsurgical pain. The animals were returned to the cage and were fed normally by their mothers.
Preparation of medullary slices. Twenty-four to 48 h after the labeling surgery, the newborn animals were deeply anesthetized with halothane as described above and then decapitated. Brains were removed from skulls within 1 min and submerged in cold (4°C) ACSF with the following composition (in mM): NaCl, 128; KCl, 3.0; NaHCO3, 24; NaH2PO4, 0.5; CaCl2, 1.5; MgCl2, 1; and D-glucose, 30. The solution was continuously bubbled with 95% O2-5% CO2, and the pH was adjusted to 7.4 before use. The cerebellum was removed from each brain, and the hindbrain was isolated with the aid of a dissection microscope. Brainstems were secured in the slicing chamber of a vibratome (VT 1000S; Leica Microsystems, Wetzlar, Germany) filled with the same ACSF. The rostral ends of the brainstems were set upward, and the dorsal surfaces were glued to an agar block facing the razor. Brainstems were sectioned serially in variable thicknesses from 30 to 200 m in the transverse plane. The compact portion of the nucleus ambiguus was used as a landmark. Once it was visible, we took a single medullary slice (500 -650 m thickness) for experimentation. One or two hypoglossal rootlets were retained on each side of the slices. The medullary slice preparation generates rhythmic inspiratory-like discharge in hypoglossal rootlets (27) . Slices were transferred to the recording chamber and superfused with ACSF (flow rate 6 -9 ml/min). The rostral cutting plane of the slice was set upward to allow fluorescent identification and patch-clamp recording of AVPNs. Bath temperature was maintained at 23 Ϯ 0.1°C, and the concentration of KCl in the ACSF was increased to 8 mM to allow steady recording of the respiratory rhythm.
Electrophysiological recording. In medullary slices, the objective AVPNs in the eNA were identified with an Olympus upright microscope (with a ϫ40 water-immersion objective lens) by the presence of fluorescence under fluorescent illumination (bandpass of emission light 330 -380 nm). Individual AVPNs were then imaged with differential interference contrast optics, infrared illumination, and then with an infrared-sensitive video detection camera to gain better spatial resolution and to visually guide and position the patch pipette onto the identified AVPNs. The patch pipette (2-4 M⍀) was normally filled with a solution with the following composition (in mM): K gluconate, 130; HEPES, 10; EGTA, 10; CaCl2, 0.1; 5=-ATP-K2, 2; MgCl2, 1 (pH 7.3), and advanced to obtain a seal over 1 G⍀ between the pipette tip and the cell membrane of the identified neuron. The membrane under the pipette tip was then ruptured with brief suction to obtain a whole-cell patch-clamp configuration. The pipette resistance and capacitance were not compensated either before or after gaining intracellular access. In voltage clamp experiments, IA-AVPNs were identified as those that showed bursting inspiratory inward synaptic currents, and clamped at Ϫ80 mV during the experiment to minimize the Cl Ϫ currents caused by activation of GABA receptors and glycine receptors. II-AVPNs were identified as those that showed bursting inspiratory outward synaptic currents when clamped at Ϫ50 mV or more positive levels, and clamped at Ϫ50 mV during the experiment to reveal both the inward glutamate currents and the outward inhibitory currents. In some experiments, for calculation of input resistance, a 5-mV, 200-ms hyperpolarizing pulse was applied to the AVPN under recording at a 4-s interval.
To obtain better recordings of IPSCs, in some experiments the patch pipette was filled with a KCl-dominated solution with the following composition (in mM): KCl, 150; HEPES, 10; EGTA, 2; and ATP-Mg, 2 (pH 7.3), and the cells were clamped at Ϫ80 mV. Under this condition, the inspiratory excitatory currents in IA-AVPNs and the inspiratory inhibitory currents in II-AVPNs were all inward. A puff pipette filled with ACSF containing the antagonists of glutamate receptors (see below) was positioned with its tip within 10 m from the neuron under recording; and those antagonists in the puff pipette were then focally applied onto the neuron under recording using a PV830 Pneumatic Picopump pressure delivery system (World Precision Instruments, Sarasota, FL). IA-AVPNs then were distinguishable from II-AVPNs because the inspiratory inward currents of the former were eliminated by the focally applied antagonists.
The patch-clamp signal was amplified with an Axopatch 700B amplifier (sampling frequency 10 kHz, filter frequency 1 kHz), digitized with a 1322A Digidata, and collected with Clampex 9.2 software (Molecular Devices, Sunnyvale, CA). The activity of the hypoglossal rootlets was recorded through a suction electrode, amplified with a BMA-931 Bioamplifier (5 kHz sampling frequency, 10 -1,000 Hz bandpass, ϫ20,000 magnification) (CWE, Ardmore, PA) and electronically integrated ( ϭ 200 ms) with an MA-1000 Moving Averager (CWE).
Drug application. In adult rats, A61603 hydrate {N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide hydrobromide}, a potent and highly selective agonist of ␣1A-adrenoceptors, was microinjected (1 pmol, in 100 nl of ACSF) into a unilateral eNA to activate ␣1A-adrenoceptors. In each rat, A61603 was microinjected only once. In some experiments, at least 20 min prior to the microinjection, atropine sulfate (0.5 mg/kg) was injected intraperitoneally to block the vagally mediated airway responses. In medullary slices, drugs were normally applied in the bath. A61603 was used at 10 or 100 nM for 6 min. In some experiments, RS100329 hydrochloride {5-Methyl-3-
, a potent and highly selective antagonist of ␣ 1A-adrenoceptors, was applied at least 10 min prior to A61603 application to block the ␣ 1A-adrenoceptor, and the subsequent A61603 application was prolonged to 10 -11 min in the continuous presence of RS100329. Strychnine (1 M) and bicuculline (50 M) were used to block glycine receptors and GABA A receptors, respectively. CNQX (50 M) and AP 5 (50 M) were used to block non-NMDA and NMDA glutamate receptors, respectively. When the neurons were recorded with the KCl-dominated pipette solution, CNQX and AP 5 were first applied focally to identify the type of AVPN, and then included in the perfusate along with strychnine or bicuculline to isolate GABAergic or glycinergic IPSCs, respectively. In experiments that examined mEPSCs, TTX (1 M) was included in the perfusate. On the day of experiment, CNQX and bicuculline were dissolved in DMSO, and all of the other drugs were dissolved in deionized water to make fresh stock solutions. The final concentration of individual drugs was achieved by dilution of the stock solution with ACSF by at least 1,000 times. In each slice, only one AVPN was tested and each agonist or antagonist of ␣ 1A-adrenoceptors was applied only once to minimize desensitization. RS100329 was purchased from Tocris Bioscience (Bristol, UK), and all of the other drugs were purchased from Sigma-Aldrich (St Louis, MO).
Data analysis. Inspiratory and expiratory airway resistance was analyzed with the Anaires2005 (Beijing Biolab) software optimized for the analysis of pulmonary functions. Spontaneous and miniature synaptic currents were analyzed with MiniAnalysis (version 4.3.1; Synaptosoft, Fort Lee, NJ) with a minimal acceptable amplitude of 10 pA. In each IA-AVPN or II-AVPN, a 2-min period during control recording, during agonist (A61603) application, during antagonist (RS100329) application, or during mixed agonist and antagonist (A61603 ϩ RS100329) application was analyzed for comparison. When analyzing sEPSCs during the inspiratory intervals, the bursting excitatory postsynaptic currents during the inspiratory phase were ignored. The phasic inspiratory inward currents in IA-AVPNs or the outward current in II-AVPNs was analyzed with Clampfit 9.2 software (Molecular Devices), and the changes were expressed as percentages of the control values. Before analyzing the phasic inspiratory inward or outward currents, selected segments of the membrane current signal were low-pass-filtered at 5 Hz with an eight-pole Bessel filter. The data from five consecutive inspiratory bursts during control recording or during drug application were averaged for comparison. Results were statistically compared with paired t-tests using Origin 8.0 software (OriginLab, Northampton, MA) and are presented as means Ϯ SE. Significance was set at P Ͻ 0.05.
RESULTS
Microinjection of A61603 into a unilateral eNA significantly increased airway resistance in anesthetized adult rats. Microinjection of A61603 (1 pmol in 100 nl of ACSF) into a unilateral eNA (n ϭ 4) caused significant increases in both inspiratory and expiratory airway resistance. These effects occurred almost instantly after the microinjection and lasted for 5-20 min before complete recovery. A representative experi-ment is shown in Fig. 1, A and B, and summarized data are shown in Fig. 1C . In contrast, in rats pretreated with atropine sulphate (0.5 mg/kg), microinjection of A61603 (1 pmol in 100 nl of ACSF) into a unilateral eNA did not cause measurable changes in either inspiratory or expiratory resistance (n ϭ 4, not shown). For comparison, microinjection of ACSF at the same volume caused only transient changes in inspiratory and expiratory resistance during the injection period of 15-20 s (n ϭ 4). Postexperiment histological examination showed that the sites of microinjection were exclusively in the eNA in all of the animals tested (n ϭ 12), as is shown for one slice in Fig. 1D .
A61603 activated both IA-AVPNs and II-AVPNs under current clamp in medullary slices. Under current clamp, IAAVPNs typically fire bursts of action potentials during the inspiratory phase, with sporadic discharges scattered during inspiratory intervals; II-AVPNs typically show rhythmic inspiratory hyperpolarization, with continuous or sporadic discharges during inspiratory intervals. In both IA-AVPNs and II-AVPNs, A61603 (10 nM) caused depolarization and a slight decrease in the amplitude of action potentials, but it significantly increased the firing rate during inspiratory intervals. In IA-AVPNs, the A61603-induced maximal depolarization ranged from 2 mV to 9 mV (mean 5 Ϯ 1 mV, n ϭ 6), and the firing rate during inspiratory intervals was 0.4 Ϯ 0.2 spikes/s before and 1.7 Ϯ 0.3 spikes/s after A61603 application, respectively (P ϭ 0.002, n ϭ 6). A representative experiment is shown in Fig. 2, A and B . In II-AVPNs, the A61603-induced maximal depolarization ranged from 3 mV to 6 mV (mean 5 Ϯ 1 mV, n ϭ 4), and the firing rate during inspiratory intervals was 1.1 Ϯ 0.6 spikes/s before and 4.3 Ϯ 0.4 spikes/s after A61603 application, respectively (P ϭ 0.031, n ϭ 4). A representative experiment is shown in Fig. 2 , C and D. The A61603-induced activation of AVPNs started within 2 min after the start of A61603 application, it lasted for 10 to 15 min, and was reversible.
A61603 significantly increased the frequency of sEPSCs and the intensity of phasic inspiratory inward currents in IA-AVPNs. In IA-AVPNs identified in medullary slices, A61603 (10 nM) caused a tonic inward current that is maximally 16 to 47 pA (mean 30 Ϯ 10 pA, n ϭ 6) in individual neurons under voltage clamp, and caused a significant increase in the frequency but not the amplitude of sEPSCs. A representative experiment is shown in Fig. 3 , A-C, and summarized data for sEPSCs are shown in Fig. 3 , E and F. A61603 also caused significant increases in the peak amplitude, duration, and area of inspiratory inward currents. For comparison, Fig.  3D shows two typical inspiratory inward currents from a representative experiment, one obtained during control recording and the other during A61603 application. Summarized data for phasic inspiratory inward currents are shown in Fig. 3G . At the end of the experiments, all of the excitatory inward currents, whether they were spontaneous or phasic, were abolished by 50 M CNQX.
The A61603-induced changes in IA-AVPNs were sensitive to RS100329, an antagonist of ␣ 1A -adrenoceptors. After pretreatment with RS100329 (1 M), A61603 (10 nM) did not cause significant changes in IA-AVPNs in either the sEPSCs or the phasic inspiratory inward currents. A representative experiment is shown in Fig. 4, A and B ; summarized data for sEPSCs are shown in Fig. 4 , C and D; and summarized data for inspiratory inward currents are shown in Fig. 4 , E-G. In addition, RS100329 (1 M) alone caused a slight outward change in the baseline current in IA-AVPNs (Fig. 4A) , and caused significant decreases in the frequency of the sEPSCs (Fig. 4C ) and in the area of the inspiratory inward currents (Fig. 4G) . In the seven IA-AVPNs pretreated with RS100329, the total application time of RS100329 averaged 26.6 min.
After preincubation with 1 M TTX, the hypoglossal bursts, as well as the associated inspiratory changes in IA-AVPNs, were abolished. Under this condition, A61603, even at a higher concentration of 100 nM, did not cause significant changes in mEPSCs in either frequency (2.3 Ϯ 0.5 Hz before vs. 2.5 Ϯ 0.3 Hz after A61603 application, P ϭ 0.78, n ϭ 4) or amplitude (25 Ϯ 1 pA before vs. 22 Ϯ 1 pA after A61603 application, P ϭ 0.14, n ϭ 4). In addition, after pretreatment with TTXcontaining ACSF, A61603 (100 nM) did not significantly alter the input resistance of IA-AVPNs (91 Ϯ 11 M⍀ before vs. 93 Ϯ 6 M⍀ after A61603 application, P ϭ 0.803, n ϭ 5), and did not cause measurable change in the baseline current.
In IA-AVPNs recorded with the KCl-dominated pipette solution, A61603 (10 nM) did not cause significant changes to the pharmacologically isolated GABAergic (n ϭ 5) or glycinergic IPSCs (n ϭ 5) in either frequency or amplitude (data not shown).
A61603 caused significant increases in the frequency of sEPSCs and in the duration and area of the inspiratory outward currents in II-AVPNs in medullary slices. In the II-AVPNs identified in vitro, A61603 (10 nM) significantly increased the frequency but not the amplitude of sEPSCs. The baseline current was not visibly altered by A61603 under the holding potential of Ϫ50 mV. A representative experiment is shown in Fig. 5A , and summarized data for sEPSCs are shown in Fig. 5 , B and C. A61603 (10 nM) also caused significant increases in the duration and area, but not in the peak amplitude, of the inspiratory outward currents, as is summarized in Fig. 5D . At the end of the experiments, all sEPSCs were abolished by 50 M CNQX, and all inhibitory outward currents, no matter whether they were spontaneous or phasic inspiratory, were abolished by a mixed application of bicuculline (50 M) and strychnine (1 M).
The A61603-induced changes in II-AVPNs were also sensitive to RS100329. After pretreatment with RS100329 (1 M), A61603 (10 nM) did not cause significant changes in II-AVPNs in either sEPSCs or phasic inspiratory outward currents. A representative experiment is shown in Fig. 6A ; summarized data for sEPSCs are shown in Fig. 6 , B and C. In addition, RS100329 (1 M) alone caused significant decreases in both the frequency and amplitude of sEPSCs (Fig. 6, A-C) . Summarized data for phasic inspiratory outward currents are shown in Fig. 6, D-F .
With pretreatment of II-AVPNs with TTX-containing ACSF and under a holding potential of Ϫ80 mV, A61603 (10 nM) did not cause significant changes in either frequency (2.6 Ϯ 0.5 Hz before vs. 2.4 Ϯ 0.3 Hz after A61603 application, P ϭ 0.53, n ϭ 3) or amplitude (15 Ϯ 1 pA before vs. 15 Ϯ 2 pA after A61603 application, P ϭ 0.54, n ϭ 3) of mEPSCs. In addition, under this condition, A61603 (10 nM) did not significantly alter the input resistance of II-AVPNs (98 Ϯ 12 M⍀ before vs. 105 Ϯ 15 M⍀ after A61603 application, P ϭ 0.11, n ϭ 7), and did not cause a measurable change in the baseline current.
In II-AVPNs recorded with the KCl-dominated pipette solution, A61603 (10 nM) did not cause significant changes to the pharmacologically isolated GABAergic (n ϭ 4) or glycinergic IPSCs (n ϭ 4) in either frequency or amplitude (data not shown).
DISCUSSION
There are six major findings in the present study. First, microinjection of A61603 into unilateral eNA significantly increased both inspiratory and expiratory airway resistance in anesthetized adult rats, and this effect was prevented by intraperitoneal preinjection of atropine. Second, in medullary slices of newborn rats, A61603 depolarized both IA-AVPNs and II-AVPNs under current clamp, and significantly increased their firing rate during inspiratory intervals. Third, in both types of AVPNs recorded under voltage clamp, A61603 significantly increased the frequency of sEPSCs. Additionally, A61603 caused a tonic inward current and significantly increased the peak amplitude, duration, and area of phasic inspiratory inward currents in IA-AVPNs. Fourth, all of the A61603-induced responses of AVPNs under voltage clamp were prevented by RS100329, a selective antagonist of ␣ 1A -adrenoceptors. In addition, RS100329 alone significantly decreased the frequency of sEPSCs in both IA-AVPNs and II-AVPNs, and significantly decreased the amplitude of sEPSCs in II-AVPNs. Fifth, in the preexistence of TTX in either IA-AVPNs or II-AVPNs, A61603 did not cause significant changes in the frequency or amplitude of mEPSCs or in input resistance, nor did it cause measurable changes in the baseline current. Sixth, A61603 did not cause significant changes in the pharmacologically isolated GABAergic or glycinergic IPSCs in either IA-AVPNs or II-AVPNs.
In anesthetized adult rats, the increase in airway resistance induced by microinjection of A61603 into a unilateral eNA was sensitive to intraperitoneal atropine, suggesting that this increase is vagally mediated. And in medullary slices of newborn rats, A61603 consistently depolarized both IAAVPNs and II-AVPNs, and significantly increased their firing rate during inspiratory intervals. These results demonstrate that in rats, activation of medullary ␣ 1A -adrenoceptors increases airway muscle tone via activation of AVPNs.
In both IA-AVPNs and II-AVPNs, A61603 increased the frequency of sEPSCs but not that of mEPSCs. These results suggest that ␣ 1A -adrenoceptors, if they are expressed in the glutamatergic neurons presynaptic to AVPNs, are more likely located on preterminal sites on axons or dendrites, or perhaps on the cell body itself. A less likely location is the presynaptic glutamatergic terminals where activation of ␣ 1A -adrenoceptors takes effect by altering action potential-dependent release of glutamate. Moreover, because the excitatory inputs to IAAVPNs are rhythmically activated, at least some of the glutamatergic neurons presynaptic to IA-AVPNs receive excitatory synaptic control from the respiratory rhythmogenic neuronal network, of which ␣ 1 -adrenergic excitatory modulation has been well characterized (1) . In the present study, A61603 enhanced not only the peak amplitude but also the duration of the inspiratory excitatory inward currents of IA-AVPNs, which suggests that this A61603-induced enhancement involves polysynaptic actions including those on the respiratory rhythmogenic neuronal network. Similarly, it is likely that the A61603-induced frequency increase of sEPSCs, at least in IA-AVPNs, involves polysynaptic actions.
Under current-clamp, A61603 depolarized both IA-AVPNs and II-AVPNs. Under voltage-clamp, A61603 typically induced a tonic inward current and significantly increased the peak amplitude of the inspiratory inward currents in IAAVPNs. These excitatory effects can be caused either solely by increased presynaptic glutamate release, or in combination with a direct postsynaptic action. In case ␣ 1 -adrenoceptors are expressed on AVPNs, their activation might independently cause inward current and potentiate the response to the glutamate released from presynaptic terminals. However, in both IA-AVPNs and II-AVPNs, and in both the absence and presence of TTX, A61603 did not cause a significant amplitude change in sEPSCs or mEPSCs. Moreover, in the presence of TTX, A61603 did not cause a significant input resistance change, nor did it cause a measurable change in the baseline current in either IA-AVPNs or II-AVPNs. These results suggest that A61603 has little if any direct postsynaptic effect on either IA-AVPNs or II-AVPNs, and that A61603-induced excitatory effects are predominantly mediated by increased presynaptic glutamate release. In individual presynaptic glutamatergic neurons, increased glutamate release can be caused by increased firing rate and prolonged action potential duration. At the network level, increased glutamate release might also include the recruitment of multiple presynaptic neurons. Increased presynaptic glutamate release might on the one hand enhance the summation of synaptic currents and, on the other hand, increase the opening probability of extrasynaptic glutamate receptor channels in the AVPNs, and consequently cause tonic inward current or depolarization.
Currently, ␣ 1 -adrenoceptors are known to consist of at least three subtypes (␣ 1A , ␣ 1B , and ␣ 1D ), and that the binding each subtype with a corresponding selective agonist activates similar intracellular signaling pathways via coupling with an excitatory G q type of G-protein. A61603 is known to be at least 35-fold more potent against ␣ 1A -adrenoceptors than against ␣ 1B -and ␣ 1D -adrenoceptors (21) ; and the ␣ 1A -adrenoceptor antagonist RS100329 is 126-and 50-fold more selective against ␣ 1A -adrenoceptors than against ␣ 1B -adrenoceptors or ␣ 1D -adrenoceptors, respectively (33) . In this study, A61603 at a low nanomolar level (10 nM) was sufficient to cause potent excitatory effects on AVPNs, and RS100329 not only blocked the A61603-induced enhancement of excitatory inputs to AVPNs, but it also independently caused significant inhibition of the baseline excitatory inputs. These results suggest that both IA-AVPNs and II-AVPNs are tonically modulated by endogenous adrenaline or noradrenaline, and that this modulation includes an excitatory effect mediated by ␣ 1 -adrenergic, particularly ␣ 1A -adrenergic, facilitation of the excitatory inputs. Physiologically, the ␣ 1 -adrenergic excitatory modulation of AVPNs might be overwhelmed by ␣ 2 -adrenergic inhibition because endogenous noradrenaline release by stimulation of the LC mainly exerts ␣ 2 -adrenergic inhibition on airway vagal tone (14) . However, under asthma-inducing/triggering conditions such as CIC or CIH, the ␣ 1 -adrenoceptors that potentially may be expressed in the glutamatergic presynaptic neurons of AVPNs might also be upregulated, as is observed in some other brainstem nuclei receiving noradrenergic projections (23, 26, 28) , leading to exaggerated ␣ 1 -adrenergic excitation of AVPNs. This predicted exaggeration of ␣ 1 -adrenergic modulation along with the reported attenuation of ␣ 2 -adrenergic (34) modulation of AVPNs might, as a result, shift the adrenergic effect on airway vagal tone from inhibitory-dominated to excitatory-dominated.
In the IA-AVPNs and II-AVPNs recorded with the KCldominated pipette solution, A61603 had no effect on pharmacologically isolated GABAergic or glycinergic IPSCs. These results further suggest that the A61603-induced activation of both types of AVPNs is mainly due to the facilitation of their excitatory inputs. These results also suggest that it is less likely that ␣ 1A -adrenoceptors are expressed in the GABAergic or glycinergic neurons projecting to the AVPNs. This latter postulate seems contradictory with the finding that A61603 also caused significant increases in the duration and area of the inspiratory outward currents of II-AVPNs. In medullary slices of newborn rats, the inspiratory bursting of the inhibitory inputs to II-AVPNs disappears after CNQX is included in the perfusate (10) , which clearly indicates that the GABAergic or glycinergic neurons presynaptic to II-AVPNs have no intrinsic rhythmicity and that their inspiratory activation depends on excitatory drive from the respiratory rhythmogenic neuronal network. Therefore, the A61603-induced enhancement of inspiratory outward currents of II-AVPNs is possibly an indirect effect, which might be secondary to the action of A61603 on the respiratory rhythmogenic neuronal network.
In conclusion, the present study has demonstrated that in rats, selective activation of ␣ 1 -adrenoceptors in the eNA increases airway vagal tone in vivo, and that this effect is primarily mediated by facilitation of the excitatory presynaptic inputs to AVPNs. 
